The global medicines supply chain is complex and vulnerable to disruptions. While USP has a long-standing legacy of addressing supply chain issues, the COVID-19 pandemic is a threat unlike any the world has seen. We are developing insights on current vulnerabilities in the supply chain and devising ways to strengthen it for the future.
Pandemic preparedness
For regulators in low- and middle-income countries.
Supply chain vulnerability
USP's Ron Piervincenzi and Mike Ganio from the American Society of Health System Pharmacists, discuss potential shortages of drugs made in China and India, and shipped throughout the world.